The administration of doxorubicin (DOX) is a widely used and highly effective chemotherapeutic drug, which is commonly used to treat endocrine-resistant or metastasized breast cancer. 2 However, over time, many patients develop resistance to DOX and exhibit poor response. 3,4 DOX resistance is a major clinical obstacle and a paramount cause of breast cancer treatment failure.
| INTRODUCTION
Breast cancer is the second most frequently diagnosed cancer and the leading cause of mortality in women worldwide. 1 Surgery and chemotherapy are the main treatments for breast cancer. Doxorubicin (DOX)
is a widely used and highly effective chemotherapeutic drug, which is commonly used to treat endocrine-resistant or metastasized breast cancer. 2 However, over time, many patients develop resistance to DOX and exhibit poor response. 3,4 DOX resistance is a major clinical obstacle and a paramount cause of breast cancer treatment failure.
Causes of DOX resistance can be broadly divided into two categories:
first, the cancer cells overexpress drug-resistant proteins and membrane multidrug pumps 5 ; alternatively, the cancer cells undergo alterations in cellular signaling pathways to suppress the DOXinduced apoptosis. Deregulation of apoptosis plays a vital role in the second type of DOX resistance, and peptidylprolyl isomerase A (PPIA)
is one of the most frequently studied drug-resistance-related proteins that play important roles in apoptosis inhibition of cancer cells. [6] [7] [8] [9] PPIA, also known as cyclophilin A (CYPA), a member of the ubiquitous peptidyl-prolyl cis-trans isomerase family, is the cytosolic binding protein of the immunosuppressive drug cyclosporin A. PPIA plays important roles in protein folding, immune regulation, cell migration, proliferation and apoptosis. [10] [11] [12] Recent studies have reported that PPIA was overexpressed in many kinds of human cancer, including breast cancer, colon cancer, kidney cancer, pancreas cancer, and lung cancer. 9 Moreover, PPIA appears to participate in cell proliferation, cell migration/invasion, and apoptosis inhibition in cancer cells. [13] [14] [15] [16] Though there are a number of studies demonstrating the link between PPIA and tumor chemoresistance, our understanding of the role of PPIA in DOX resistance of breast cancer is limited. 
| MTT assay
Cells were seeded into 96-well culture plates at the initial density of 
| Real-time PCR analysis
Total RNA was extracted using Universal RNA Extraction Kit (TaKaRa Bio, China) and then reverse-transcribed into cDNA using Prime- 
| Luciferase reporter assay

| Statistical analyses
All data are presented as mean ± SE. Data were assessed by one-way analysis of variance, followed by Student-Newman-Keuls post hoc test. P < 0.05 is considered statistically significant.
| RESULTS
| miR-192-5p expression is downregulated and PPIA expression is upregulated in MCF-7 and MCF-7/ADR
Because many miRNAs are deregulated in cancer, we tested whether miR-192-5p was also deregulated in human breast cancer. Because previous studies showed that PPIA was associated with drug resistance in certain kinds of tumor, 8, 27 we also detected the expression of PPIA in the three cell lines. We found that relative to MCF-10A, PPIA level was remarkably increased in MCF-7 and in MCF-7/ADR ( Figure 1B ).
We further determined the IC 50 of DOX in MCF-10A, MCF-7, and MCF-7/ADR. As shown in Figure 1C , the inhibition rate of DOX of MCF-10A, MCF-7, and MCF-7/ADR are 62.1%, 47.6%, and 13.3%, respectively. These data showed that upregulation of PPIA and downregulation of miR-192-5p may be involved in DOX-resistance of breast cancer cells. were both significantly increased ( Figure 2D ).
| miR-192-5p overexpression increases sensitivity to DOX and increases cell apoptosis in breast cancer cell
| miR-192-5p transfection activates JNK-dependent apoptosis
Because JNK mediates DOX-induced apoptosis in cancer cells and plays important roles in apoptosis, 28 we examined the effect of miR-192-5p transfection on JNK pathway. We found that miR-192-5p transfection significantly activated JNK pathway both in MCF-7 and MCF-7/ADR cells ( Figure 3A) .
We further examined the effects of miR-192-5p transfection on other apoptosis-related pathways. Western blot and RT-PCR results
showed that miR-192-5p transfection significantly increased BAD and caspase 9 expression, and decreased Bcl-2 and PPIA expression ( Figure 3B ,C).
| PPIA is a direct target of miR-192-5p
Luciferase reporter assay was performed to determine whether an association exists between miR192-5p and PPIA. In our study, we found that PPIA expression was higher in MCF-7
relative to MCF-10A, while PPIA expression in MCF-7/ADR was even higher. This is not surprising because higher expression of PPIA is very common in many different kinds of cancer and is closely related to chemoresistance. 9 Our study also found that miR-192-5p transfectioninduced suppression of PPIA was accompanied by decreased expression of Bcl-2 and increased activation of JNK. This is plausible because PPIA expression is positively correlated with Bcl-2 levels, and PPIA is known to reduce the expression and function of JNK pathways. 29, 34 We also provided the first evidence that PPIA is a direct target of 
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